Incidence of Headache Following an Unintentional Dural Puncture

November 15, 2021 updated by: Feyce M. Peralta, MD, MS, Northwestern University

Incidence of Post-Dural Puncture Headache Following Unintentional Dural Puncture: A Randomized Trial of Intrathecal Morphine Versus Saline

The purpose of this study is to evaluate the use of intrathecal morphine administration following an unintentional dural puncture, to decrease the incidence of post dural puncture headaches (PDPH) in obstetric patients.

Study Overview

Detailed Description

Unintentional dural puncture is a known risk of neuraxial techniques, occurring in roughly 1% of all epidural catheter placements. The incidence of post dural puncture headaches(PDPH) after unintentional dural puncture (UDP) is 50-80%. A PDPH is defined as a headache that occurs following a dural puncture, worsens within 15 minutes after sitting or standing and improves within 15 minutes after lying, with at least one of the following: neck stiffness, tinnitus, hypacusia, photophobia, or nausea. The headache develops within 5 days after dural puncture and resolves either spontaneously within 1 week or within 48 hours after effective treatment of the spinal fluid leak.

The rates of PDPH following unintentional dural puncture with placement of an intrathecal catheter will be compared in two groups: intrathecal morphine (treatment) versus intrathecal saline (control) administered 1-2 hours after delivery, followed by immediate catheter removal. Patients randomized to the treatment group (morphine) will receive preservative-free morphine 0.3 mL (150 mcg) intrathecally. Those randomized to the control group will receive normal saline 0.3 mL intrathecally. After administration of intrathecal morphine, all patients will have their respirations monitored every hour for a period of 12 hours and then every two hours for a period of 12 hours. On postpartum days 1-5, all patients will be visited daily while inpatient and/or contacted by phone after discharge from the hospital.

PDPH can lead to significant morbidity and negatively impact patient satisfaction with postpartum recovery. Along with headache, patients may develop cranial nerve palsy during the postpartum period leading to permanent disability. In addition, new mothers are unable to bond with their babies due to headache and associated symptoms of nausea, vomiting and limited mobility secondary to pain. Therefore, an effective intervention to decrease the risk of PDPH after UDP would be useful.

Study Type

Interventional

Enrollment (Actual)

68

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Illinois
      • Chicago, Illinois, United States, 60611
        • Northwestern Memorial Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Postpartum patients following vaginal delivery
  • Unintentional dural puncture
  • Functioning intrathecal catheter
  • Patients must be 18 years of age or older
  • English speaking.

Exclusion Criteria:

  • History of previous PDPH
  • Body mass index BMI > 40 kg/m2
  • History of obstructive sleep apnea (OSA)
  • Morphine allergy
  • Patients who receive Cesarean delivery

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Morphine
Patients randomized to the treatment group (morphine) will receive preservative-free morphine 0.3 mL (150 mcg) intrathecally.
The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
Other Names:
  • Duramorph
Placebo Comparator: Saline
Patients randomized to the control group will receive normal saline 0.3 mL intrathecally.
The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
Other Names:
  • Normal Saline

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Participants Who Report Post Dural Puncture Headaches
Time Frame: 5 days
Participants who report post dural puncture headaches from delivery to postpartum day 5
5 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Severity of Post Dural Puncture Headache
Time Frame: Time of unintentional dural puncture to postpartum day 5
Severity of post dural puncture headache on a numerical rating scale 0= no pain and 10= worst pain imaginable from the time of delivery to postpartum day 5.
Time of unintentional dural puncture to postpartum day 5
Treatment Method for Headache
Time Frame: Unintentional dural puncture - Postpartum day 5
Treatment method completed for unintentional dural puncture headache.
Unintentional dural puncture - Postpartum day 5
Number of Participants With Cranial Nerve Symptoms
Time Frame: 5 days
The number of participants who experience cranial nerve symptoms up to 5 days after the unintentional dural puncture.
5 days
Repeat Epidural Blood Patch
Time Frame: After first epidural blood patch to 5 days after delivery
Repeated epidural blood patch for headache pain after unintentional dural puncture.
After first epidural blood patch to 5 days after delivery
Presenting Day of Headache
Time Frame: Dural puncture to 5 days after delivery
Presenting day of headache after unintentional dural puncture
Dural puncture to 5 days after delivery
Number of Participants With Duration in Days of Headache After Unintentional Dural Puncture.
Time Frame: 5 days
The duration in days of headaches the participants experience after an unintentional dural puncture
5 days
Greatest Level of Headache Pain Experienced With the Unintentional Dural Puncture
Time Frame: 5 days
Greatest reported headache pain associated with unintentional dural puncture reported on a scale of 0= no pain to 10= worst pain imaginable.
5 days
Intrathecal Catheter Dwell Time
Time Frame: Insertion time to removal in minutes
Intrathecal catheter dwell time(time from insertion to time of removal in minutes).
Insertion time to removal in minutes
Intrathecal Infusion Volume
Time Frame: Time of insertion of catheter to time catheter removed
Intrathecal infusion volume in milliliters
Time of insertion of catheter to time catheter removed
Mode of Delivery
Time Frame: up to 10 hours after intrathecal catheter placed
Mode of delivery of the baby (vaginal delivery or instrumented vaginal delivery)
up to 10 hours after intrathecal catheter placed

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Feyce Peralta, MD, Northwestern University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2011

Primary Completion (Actual)

March 1, 2019

Study Completion (Actual)

March 1, 2019

Study Registration Dates

First Submitted

October 31, 2013

First Submitted That Met QC Criteria

October 31, 2013

First Posted (Estimate)

November 7, 2013

Study Record Updates

Last Update Posted (Actual)

November 17, 2021

Last Update Submitted That Met QC Criteria

November 15, 2021

Last Verified

November 1, 2021

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Postdural Puncture Headache

Clinical Trials on Morphine

3
Subscribe